Peptinovo Biopharma, LLC was founded to create a novel, low-cost targeted nanoparticle formulation that makes chemo drugs safer and more effective. The company has completed in vivo concept verification. Founders have supported the company investment to date.
The company is seeking outside investment as well as strategic partnerships. We are currently raising $1.5M with a $3.5M follow on. Funds will be used for development, pre-clinical testing, and additional IP filing. A second priced round will fund Phase 1 human trials. The company is also seeking non-dilutive NIH SBIR grants, plus a partnership and grants with leading cancer foundations and internal NIH/NCI faculty.
Intellectual Property: Foundational patent was issued in January 2020 and additional provisional have been filed. Broad PCT coverage and broad-based US filing.